Search results for:
Plasma donors have a lasting impact on those of us with hemophilia
On Nov. 19, I had the privilege of participating in a panel at the Plasma Protein Therapeutics Association’s Plasma Protein Forum in Washington, D.C. Robert F. Sidonio Jr., MD, a pediatric hematologist-oncologist, joined Nikole Scappe-Hagen, the National Bleeding Disorders Foundation’s manager of education, and I to lead…
Coalition for Hemophilia B women’s retreat was full of highlights
The Coalition for Hemophilia B held its annual women’s retreat Nov. 14-17 in Alpharetta, Georgia. Initially scheduled for September, the event was postponed due to Hurricane Helene. Despite the delay, the retreat was worth the wait, and I was honored to attend. Since September, I have proudly served as…
Hympavzi approved in EU for hemophilia A, B, without inhibitors
Pfizer’s Hympavzi (marstacimab) has been approved in the European Union (EU) to prevent or reduce the frequency of bleeding episodes in adults and children, ages 12 and older, with severe hemophilia A or hemophilia B who weigh at least 35 kg (77 pounds) and haven’t developed neutralizing…
Siblings’ shared hemophilia experience creates a stronger bond
My sons have severe hemophilia A and are 10 years apart. Such a considerable age difference once posed challenges, especially when they were younger. Back then, my oldest son, Julian, felt he and his brother, Caeleb, didn’t have common interests. I reminded Julian that siblings close in age…